ArticleAntimicrobial agents and chemotherapy2017
Pyrazinoic Acid Inhibits a Bifunctional Enzyme in Mycobacterium tuberculosis.
Article in Antimicrobial agents and chemotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 39 citations in OpenAlex.
- Selective inhibition of Mycobacterium tuberculosis GpsI unveils a novel strategy to target the RNA metabolism.Nucleic acids research · 2025Article
- Targeting the bacterial stringent response to combat human pathogens.Frontiers in immunology · 2025Review
- Synthesis, Docking, and Biological Studies of Pyrazine Derivatives as Antimycobacterial Agents.Medicinal chemistry (Shariqah (United Arab Emirates)) · 2025Article
- Antibiotic tolerance among clinical isolates: mechanisms, detection, prevalence, and significance.Clinical microbiology reviews · 2024Review
- Pyrazinoic acid, the active form of the anti-tuberculosis drug pyrazinamide, and aromatic carboxylic acid analogs are protonophores.Frontiers in molecular biosciences · 2024Article
- Tale of Twin Bifunctional Second Messenger (p)ppGpp Synthetases and Their Function in Mycobacteria.ACS omega · 2023Review
- Polynucleotide Phosphorylase Mediates a New Mechanism of Persister Formation in Escherichia coli.Microbiology spectrum · 2023Article
- InJournal of bacteriology · 2022Article
- Activity of Pyrazinamide againstAntibiotics (Basel, Switzerland) · 2021Article
- Targeting theFrontiers in microbiology · 2021Review
- The Bewildering Antitubercular Action of Pyrazinamide.Microbiology and molecular biology reviews : MMBR · 2020Review
- Article
- RelZ-Mediated Stress Response inJournal of bacteriology · 2020Article
- Potential Impact of the Multi-Target Drug Approach in the Treatment of Some Complex Diseases.Drug design, development and therapy · 2020Review
- Detection of Novel Gene Mutations Associated with Pyrazinamide Resistance in Multidrug-ResistantInfection and drug resistance · 2020Article
- Characterization ofFrontiers in microbiology · 2020Article
- Pharmacological and Molecular Mechanisms Behind the Sterilizing Activity of Pyrazinamide.Trends in pharmacological sciences · 2019Review
- Pyrazinoic Acid Inhibits the Bifunctional Enzyme (Rv2783) inPathogens (Basel, Switzerland) · 2019Article
- Proteomic and transcriptomic experiments reveal an essential role of RNA degradosome complexes in shaping the transcriptome of Mycobacterium tuberculosis.Nucleic acids research · 2019Article
- Mechanisms of Bacterial Tolerance and Persistence in the Gastrointestinal and Respiratory Environments.Clinical microbiology reviews · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 3 countries.
Funding
Abstract
Pyrazinamide (PZA), an indispensable component of modern tuberculosis treatment, acts as a key sterilizing drug. While the mechanism of activation of this prodrug into pyrazinoic acid (POA) by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.